Adobe (ADBE) operates as a diversified software company worldwide. Its digital medical segment provides tools and solutions that enable customers monetize their digital content anywhere. The company�� digital marketing segment provides solutions for optimizing the operation of digital advertising businesses. The print and publishing segment provides products that address diverse market opportunities. One of the company�� flagship products is Adobe Creative Cloud. This is a service that enables consumers to download and install the latest version of their creative products.
Numbers at a Glance
Adobe is redefining the digital marketing sector. In the first quarter, it achieved $1 billion in revenues, with non-GAAP earnings per share of 30 cents. The company�� Adobe Creative Cloud grew to just under $1billion. Adobe exited the quarter with over 1.8 million subscriptions. This was an improvement from the 405,000 recorded at the end of the fourth quarter. Revenues from marketing cloud software subscriptions rose 24% on a year-on-year basis to $267 million. Adobe�� total subscription revenue soared 89% to $423.6 million.
Hot Telecom Stocks For 2015: NewLink Genetics Corp (NLNK)
NewLink Genetics Corporation (NewLink), incorporated on June 4, 1999, is a development-stage company. The Company is a biopharmaceutical company focused on discovering, developing and commercializing immunotherapeutic products for cancer treatment. Its portfolio includes biologic and small-molecule immunotherapy product candidates focused to treat a range of oncology indications. Its product candidate, HyperAcute Pancreas cancer immunotherapy (HyperAcute Pancreas), is being studied in a Phase-III clinical trial in surgically-resected pancreatic cancer patients that is being performed under a Special Protocol Assessment (SPA), with the United States Food and Drug Administration (FDA). It has three additional product candidates in clinical development, including its HyperAcute Lung cancer immunotherapy (HyperAcute Lung), which is being studied in a Phase-I/II clinical trial conducted at the National Cancer Institute (NCI), and its HyperAcute Melanoma cancer immunotherapy (HyperAcute Melanoma), which is being studied in an investigator-initiated Phase-II clinical trial.
The Company�� HyperAcute product candidates are based on its HyperAcute immunotherapy technology, which is designed to stimulate the human immune system. It is also conducting small-molecule based research and development to produce new drugs capable of breaking the immune system's tolerance to cancer through inhibition of the indoleamine-(2,3)-dioxygenase (IDO), pathway. It is engaged in the study of IDO pathway inhibitor product candidate, d-1-methyltryptophan (D-1MT), in collaboration with the NCI, in two Phase 1B/II clinical trials.
HyperAcute Cancer Immunotherapy Product Candidates
In May 2010, the Company initiated Phase-III clinical trial for HyperAcute Pancreas. Its second product candidate, HyperAcute Lung, is in a Phase I/II clinical trial that is enrolled with 54 patients for the treatment of refractory, recurrent or metastatic nonresectable non-small cell lung cancer (NSCLC). Its Hyper! Acute Melanoma product candidate is being studied in an investigator-initiated, fully enrolled 25 patient Phase-II clinical trial for the treatment of advanced melanoma.
HyperAcute Cancer Immunotherapy Technology
The Company�� HyperAcute immunotherapies operate by exploiting a natural barrier present in humans that protects against infection being transmitted from other mammals. This barrier is related to the enzyme, alpha (1,3) galactosyl transferase, which is expressed in the cells of lower mammals. The presence of this enzyme results in the expression of a non-human form of carbohydrate called alpha (1,3) galactosyl carbohydrates (a-Gal), on the surface of affected cells. Its HyperAcute immunotherapy product candidates are composed of irradiated, live, allogeneic human cancer cells modified to express the gene that makes a-Gal epitopes. This exposure to a-Gal stimulates the human immune system to attack and destroy the immunotherapy cells on, which a-Gal is present by activating complement.
IDO Pathway Inhibitor Product Candidate
The Company is developing D-1MT, a small-molecule, orally bioavailable product candidate designed to inhibit the IDO pathway. In preclinical models, IDO pathway inhibitors have shown anti-tumor effects in combination with radiotherapy, chemotherapy, targeted therapy or immunotherapy. Through its collaboration with the NCI, it is studying D-1MT in two Phase 1B/II safety and efficacy clinical trials in various chemotherapy and immunotherapy combinations. One clinical trial combines D-1MT with an Ad-p53 autologous dendritic cell vaccine for solid malignancies with p53 mutations, such as lung, breast and colon cancers. The other clinical trial involves the combined use of D-1MT and Taxotere for patients with advanced stage solid tumors, for which Taxotere is the standard-of-care treatment, such as metastatic breast, prostate, ovarian and lung cancers.
Advisors' Opinion:- [By Jayson Derrick]
NewLink Genetics (NASDAQ: NLNK) announced that it will discontinue the phase 3 IMPRESS clinical trial of algenpantucel-L for patients with pancreatic cancer. The company intends to regroup and ��athering additional, more mature data in support of our mission to provide improved treatment options for patients with pancreatic cancer.��Shares fell 16.20 percent, closing at $31.60.
- [By Jake L'Ecuyer]
In trading on Thursday, healthcare shares were relative laggards, down on the day by about 0.64 percent. Top decliners in the sector included Sunesis Pharmaceuticals (NASDAQ: SNSS), off 5.6 percent, and NewLink Genetics (NASDAQ: NLNK), down 6.3 percent.
Top Diversified Bank Stocks To Watch For 2014: Arcadis NV (ARCAD)
Arcadis NV is a Netherlands-based international engineering and consultancy firm, providing consultancy, design, engineering and management services in infrastructure, water, environment and buildings. The Company develops, designs, implements, maintains and operates projects for companies and governments. The Company divides its business into four business lines: Infrastructure, which encompasses services for transportations, land development, energy and mining; Water, focused on water planning, wastewater and water management and consulting services; Environment, focused on activities that protect the environment and enhance sustainability, and Buildings, related to homebuilding as well as commercial and industrial buildings and facilities construction. Additionally, it works in partnership with UN-HABITAT, the United Nations agency for human settlements. Advisors' Opinion:- [By Sofia Horta e Costa]
Companies like Expedia Inc. (EXPE), which provides online travel booking services, and Arcadis NV (ARCAD), a Dutch designer of bridges and dikes, are likely to increase profit at a faster pace than larger firms during an improving economy, Duret said. Smaller companies are also less leveraged, with U.S. mid-caps holding 46 percent less debt per share than firms listed on the S&P 500, data compiled by Bloomberg show.
Top Diversified Bank Stocks To Watch For 2014: Neuralstem Inc (CUR)
Neuralstem, Inc., incorporated in 1997, is a development-stage company focused on the development and commercialization of treatments for central nervous system disease based on transplanting human neural stems cells and the use of small molecule drugs. The Company has developed and maintains a portfolio of patents and patent applications that form base for its research and development efforts in the area of neural stem cell research. The Company's focus is the development of methods to generate replacement cells from neural stem cells.
In October of 2011, the Company announced that after reviewing safety data from the first 12 patients, the FDA granted approval for the trial to advance to transplanting patients in the cervical (upper back) region for the last six patients in the trial. As of December 31, 2011, the Company had treated 14 patients. In February of 2011, the Company commenced a Phase Ia clinical trial of its drug compound, NSI-189, which is being developed for the treatment of depressive disorder and other psychiatric indications. In October of 2011, the Company completed the Phase Ia portion of the trial. In December of 2011, the Company received approval from the FDA to commence the Phase Ib portion of the trial.
During the year ended December 31, 2011, the Company was selected as the primary subcontractor for the United States Department of Defense (DOD) contract to develop human neural stem cell technology for the treatment of cancerous brain tumors. The Company commenced work on the project in May 2011. The Company has developed and patented a series of small molecule compounds (low molecular weights organic compounds which can efficiently cross the blood/brain barrier).
Advisors' Opinion:- [By John Udovich]
Summer and the slow news for the market that usually comes with it�is over with and both stem cell researchers or small� cap stem cell stocks like Advanced Cell Technology, Inc (OTCBB: ACTC), Neuralstem, Inc (NYSEMKT: CUR), NeoStem Inc (NASDAQ: NBS), International Stem Cell Corp (OTCMKTS: ISCO)�and BioRestorative Therapies (OTCBB: BRTX) having news for investors and traders alike. Consider the following:
- [By Roberto Pedone]
Neuralstem (CUR) is a biotechnology company, which is engaged in the development and commercialization of treatments for central nervous system disease based on transplanting human neural stem cells and the use of small molecule drugs. This stock closed up 6.1% to $1.72 in Thursday's trading session.
Thursday's Range: $1.59-$1.72
52-Week Range: $0.49-$1.96
Thursday's Volume: 590,000
Three-Month Average Volume: 474,694From a technical perspective, CUR ripped higher here right above its 50-day moving average of $1.57 with above-average volume. This move is quickly pushing shares of CUR within range of triggering a major breakout trade above a former double top area. That trade will hit if CUR manages to take out some near-term overhead resistance levels at $1.75 to $1.79 with high volume.
Traders should now look for long-biased trades in CUR as long as it's trending above its 50-day at $1.57 or above more key support levels at $1.55 to $1.43 and then once it sustains a move or close above those breakout levels with volume that hits near or above 474,694 shares. If that breakout hits soon, then CUR will set up to re-test or possibly take out its 52-week high at $1.96. Any high-volume move above that level will then give CUR a chance to tag $2.20 to $2.50.
- [By GuruFocus]
George Soros (Trades, Portfolio) just reported his first quarter portfolio. He buys Citrix Systems Inc, Baker Hughes Inc, Comcast Corp, Spansion Inc, etc during the 3-months ended 03/31/2014, according to the most recent filings of his investment company, Soros Fund Management LLC. As of 03/31/2014, Soros Fund Management LLC owns 305 stocks with a total value of $10.1 billion. These are the details of the buys and sells.New Purchases: BHI, CODE, CTRP, CLI, AVB, COMM, CNQ, AGO, AUY, ATML, ASH, BXMT, CSTM, AEM, CMA, ARE, CHKP, AUQ, BEAV, CX, ADSK, AALCP, BLK, AIG, BIIB, ADEP, AMRI, ARWR, ATHX, BALT, BCRX, BEAT, CFX, CLFD, CUR, CODE,Added Positions: CTXS, CMCSA, CNP, ALTR, BRCD, CBS, CRM, CHTR, CCJ, CIEN, BIDU, ALLE, ABT, CDNS, ACT,Reduced Positions: AAPL, CCI, AMT, ABBV, AAL, BITA, AL, ANGI, ARIA, CBST, BA, BIRT, EXAR,Sold Out: C, BAC, CRI, AMZN, AGN, CF, BRCM, COTY, BMY, AMCX, CAR, A, ADBE, AFL,For the details of George Soros (Trades, Portfolio)'s stock buys and sells, go to http://www.gurufocus.com/StockBuy.php?GuruName=George+SorosThis is the sector weightings of his portfolio:Technology18.9%Energy14%Healthcare8.3%Consumer Defensive8.2%Communication Services8.1%Consumer Cyclical5.4%Industrials5.1%Basic Materials4.9%Financial Services2.5%Real Estate1.9%Utilities0.5%These are the top 5 holdings of George Soros (Trades, Portfolio)1. Teva Pharmaceutical Industries Ltd (TEVA) - 10,310,041 shares, 5.4% of the total portfolio. Shares added by 10.67%2. Herbalife Ltd (HLF) - 4,901,337 shares, 2.8% of the total portfolio. Shares added by 52.9%3. EQT Corp (EQT) - 2,573,814 shares, 2.5% of the total portfolio. Shares added by 3.27%4. Adecoagro SA (AGRO) - 25,915,076 shares, 2.1% of the total portfolio.5. Halliburton Co (HAL) - 3,596,353 shares, 2.1% of the total portfolio. Shares reduced by 20.73%New Purchase: Baker Hughes Inc (BHI)George Soros (Trades, Portfolio) initiated holdings in Baker Hughes Inc. His purchase prices were between $51.82 and $65.27, with an estimated
- [By Roberto Pedone]
An under-$10 biotechnology player that's starting to enter breakout territory is Neuralstem (CUR), which is engaged in the development and commercialization of treatments for central nervous system disease based on transplanting human neural stem cells and the use of small molecule drugs. This stock has been exploding to the upside in 2013, with shares up big by 139%.
If you take a look at the chart for Neuralstem, you'll notice that this stock has been uptrending strong for the last month and change, with shares pushing higher from its low of $2.15 to its intraday high of $2.62 a share. During that uptrend, shares of CUR have been consistently making higher lows and higher highs, which is bullish technical price action. That move has now started to push shares of CUR above a key downtrend line, which is bullish technical price action.
Traders should now look for long-biased trades in CUR if it manages to break out above some near-term overhead resistance levels at $2.75 to $2.97 a share, and then once it takes out its 52-week high at $3.02 a share with high volume. Look for a sustained move or close above those levels with volume that hits near or above its three-month average action of 1.10 million shares. If we get that move soon, then CUR will set up to enter new 52-week-high territory, which is bullish technical price action. Some possible upside targets off that move are $4 to $5 a share.
Traders can look to buy CUR off weakness to anticipate that breakout and simply use a stop that sits right below some key near-term support levels at $2.28 to $2.15 a share. One can also buy CUR off strength once it clears those breakout levels with volume and then simply use a stop that sits a comfortable percentage from your entry point.
Top Diversified Bank Stocks To Watch For 2014: Qatar Investment Fund PLC (QIF)
Qatar Investment Fund plc, formerly Epicure Qatar Equity Opportunities plc, is a closed-end investment company established to invest primarily in quoted equities of Qatar and other Gulf Co-operation Council (GCC) countries. Its investment objective is to capture, principally through the medium of the Qatar Exchange by investing in listed companies or companies to be listed. It also invests in listed companies, pre-initial public offer (IPO) companies, in other GCC countries. As of June 30, 2010, the Company had a portfolio of 22 investments in quoted companies in the Gulf, with 17 of them being in Qatar, four investments in United Arab Emirates and one in Kuwait. As at June 30, 2010, the top five holdings of the Company are Qatar National bank, Industries Qatar, Commercial Bank of Qatar, Qatar Islamic Bank and Rayan Bank. The Company�� wholly owned subsidiary is Epicure Qatar Opportunities Holdings Limited. The investment manager of the Company is Epicure Managers Qatar Limited. Advisors' Opinion:- [By Vivian Lewis]
The fund also operates to cut tax liabilities. EXG executes timely trades to capture additional qualified dividend income (QIF) subject to capital gains taxes which are usually lower than income taxes.
Top Diversified Bank Stocks To Watch For 2014: Arch Capital Group Ltd.(ACGL)
Arch Capital Group Ltd., together with its subsidiaries, provides insurance and reinsurance products worldwide. It operates in two segments, Insurance and Reinsurance. The Insurance segment offers casualty; construction; executive assurance; healthcare; collateral protection, debt cancellation, and service contract reimbursement products; national accounts casualty; professional liability; programs; property, energy, marine, and aviation; surety; and travel and accident insurance products. It also provides other insurance products, such as excess workers compensation and employers' liability insurance coverages for qualified self-insured groups, associations, and trusts; captive insurance programs; and accident, disability, and medical plan insurance coverages for employer groups, medical plan members, students, and other participant groups. This segment markets its products through a network of licensed independent retail and wholesale brokers. The Reinsurance segment rei nsures third party liability and worker?s compensation exposures; individual property risks that include personal lines and commercial property exposures; other specialty lines, including surety, accident and health, workers' compensation catastrophe, multi-peril crop, trade credit, and political risk; catastrophic perils, such as hurricane, earthquake, flood, tornado, hail, and fire; marine business, which includes coverage for hull, cargo, and transit and offshore oil and gas operations, as well as aviation business that comprises coverage for airline and general aviation risks; and non-traditional business to provide insurers with risk management solutions. This segment markets its reinsurance products through brokers, as well as directly with the ceding companies. The company was founded in 1995 and is headquartered in Hamilton, Bermuda.
Advisors' Opinion:- [By Holly LaFon]
Arch Capital (ACGL)'s Dinos Iordanu recently described to our analysts how he met me in 2001. Before we invested in his business, we asked him all sorts of personal questions about how he came to America from Cyprus; whether or not his wife had a job; and how big was his house? He told our analysts that "Ron was trying to get a sense of me. He wanted to understand how I viewed risk. No one else asked us such questions. They were the right questions since you were investing in our business, which was assuming underwriting risk on your behalf. "We got it right with Dinos and have about quadrupled our money in the past twelve years, not exactly the most propitious time to invest in stocks! Of course, there can be no assurance that future investments will be as profitable��lthough you can be assured that we will continue to work hard to try to achieve similar results.
- [By Ben Levisohn]
For the past several years, Berkshire has contrasted its own cost-free float provided by profitable underwriting against the industry�� (unimpressive) tendency to lose money on underwriting while generating net returns from investment income. So far, so good. Less edifying, though, is the repeated contrast of Berkshire�� track record of profitability to State Farm��…even though, as a mutual company, State Farm�� profitability goals are inherently different from for-profit insurers like Berkshire. It�� true that through year-end 2013, Berkshire�� underwriters have ��ow operated at an underwriting profit for eleven consecutive years,��but so have ACE (ACE), American Financial (AFG),� AmTrust Financial (AFSI), Arch Capital (ACGL), Chubb (CB), HCC (HCC), Progressive (PGR), RLI (RLI), and W.R. Berkley (WRB), any or all of whom provide a more meaningful comparison than contrasting Berkshire�� results to a company that�� not out to produce a profit in the first place.
Top Diversified Bank Stocks To Watch For 2014: AllianceBernstein Global High Income Fund Inc (AWF)
AllianceBernstein Global High Income Fund, Inc., (the Fund), formerly Alliance World Dollar Government Fund II, Inc. is a non-diversified, closed-end management investment company. This Fund seeks high current income and secondarily, capital appreciation. Under normal circumstances, the Fund will invest at least 65% of its total assets in sovereign debt obligations issued or guaranteed by foreign governments. Up to 35% of the Fund's investments may comprise high-yielding, high-risk fixed-income securities issued by United States corporations. AllianceBernstein Investments, Inc., an affiliate of AllianceBernstein L.P., is the manager of the Fund.
The Fund is permitted to invest, without limit, in securities denominated in non-United States currencies, as well as those denominated in the United States dollar. The Fund may also invest, without limit, in sovereign debt securities issued by emerging and developed nations and in debt securities of United States and non-United States corporate issuers.
Advisors' Opinion:- [By Adam Aloisi]
The following chart takes a comparative look at some widely held ETFs/CEFs holding different types of bonds. The objective is to visualize not only how much these products cost, but also to break down the percent of total yield depleted by management fees. I define total yield as current annualized yield plus net fees - in other words the yield of the fund if there were no management fees attached. The funds we will examine are aforementioned BND, iShares 20+ Treasury Bond (TLT), iShares High-Yield Corporate (HYG), Nuveen Municipal Value (NUV), Eaton Vance Limited Duration (EVV) and Alliance Bernstein Global High-Yield (AWF).
No comments:
Post a Comment